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Abstract 
Roles for B-Raf Kinase in the Specific Regulation of α4β1 Integrin 
in T Cells 
Wells Shaw Brown 
Advisory Professor: Bradley McIntyre, Ph.D. 
  
 
The regulation of integrin-mediated adhesion is of vital importance to adaptive and 
innate immunity.  Integrins are versatile proteins and mediate T cell migration and 
trafficking by binding to ECM or other cells, as well as initiating intracellular 
signaling cascades promoting survival or activation.   The mitogen activated-protein 
kinase (MAPK) pathway is known to be downstream from integrins and regulate 
survival, differentiation, and motility.  However, secondary roles for canonical MAPK 
pathway members are being discovered.  We show chemical inhibition of RAF by 
Sorafenib or shRNA-mediated knockdown of B-Raf reduces T cell resistance to 
shear stress to α4β1 integrin ligands vascular cell adhesion molecule-1 (VCAM-1) 
and fibronectin (FN), while inhibition of MEK/ERK by U0126 had no effect.  
Microscopy showed that RAF inhibition leads to significant inhibition of T cell 
spreading on VCAM-1.  The association of α4β1 integrin with the actin cytoskeleton 
was shown to be dependent on B-Raf activity or expression, while α4β1 integrin 
affinity for soluble VCAM-1 was not.  These effects were shown to be specific for 
α4β1 integrin, and not other integrins such as α5β1 or LFA-1, or a variety of 
membrane proteins.  We demonstrate a novel role for B-Raf in the selective 
regulation of α4β1 integrin-mediated adhesion.  
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Chapter 1 
 
General Background 
 
 
The research presented in this document will be of significant impact to the field of T 
cell adhesion. This work is also significant to the field of human disease, by both the 
direct demonstration of previously unidentified consequences of a clinically used 
chemotherapeutic agent and the implications of a novel therapeutic mechanism by 
which to control T cell migration. T cells (leukocytes) are fundamentally different 
from most other cell types, in that most cell types are confined to a specific tissue or 
organ, while T cells are found in almost all tissues and organs in the body. 
Therefore, the ability of T cells to move throughout the body is a fundamental 
process to their function as central controllers and effectors of the adaptive immune 
response (1). 
T Cells and the Adaptive Immune Response 
The innate and adaptive immune systems are the body’s defense against infection 
and disease (2). Both innate and adaptive immune systems depend upon 
leukocytes. However, the innate immune system is non-specific and largely involves 
macrophages and granulocytes, such as neutrophils, eosinophils, and basophils. 
The innate immune system recognizes and responds to pathogens in a generic way 
that cannot adapt to a specific pathogen; while the adaptive immune system is 
characterized by specificity and memory, and depends upon lymphocytes.  
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T Cell Migration 
All the cellular elements of the blood originate from hematopoietic stem cells in the 
bone marrow. In the bone marrow, some hematopoietic stem cells differentiate into 
the common lymphoid progenitor, which differentiates into natural killer (NK) cells, 
and precursor B and T lymphocytes. While precursor B lymphocytes stay in the 
bone marrow for their maturation, precursor T lymphocytes migrate to the thymus to 
undergo their maturation (Figure 1)	  (3). The central or primary lymphoid organs are 
the bone marrow and the thymus, and the B and T lymphocytes derive their name 
according to their site of maturation. Once mature, so-called naïve lymphocytes 
enter the bloodstream to migrate to the peripheral lymphoid organs, such as lymph 
nodes, spleen, and mucosal lymphoid tissues (4).  
T Cell Maturation 
B and T lymphocytes are also distinguished by the expression of antigen receptors. 
The T cell receptor (TCR) is composed of an alpha and beta chain that functions in 
a complex with CD3 family members. T lymphocytes also express a CD4 or CD8 
coreceptor that is necessary for TCR engagement with the major histocompatibility 
complex (MHC). CD4+ T cells recognize MHC class II molecules loaded with 
peptides processed from exogenous antigens, and CD8+ T cells recognize MHC 
class I molecules loaded with peptides processed from endogenous antigens. CD4+ 
T cells are known as helper T cells, and once activated, naïve CD4+ T cells 
differentiate into several subtypes that are responsible for many immunologic 
processes, such as the activation of cytotoxic T cells, the maturation of B cells into 
plasma cells, and the production of many different cytokines.  CD8+ T cells are  
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Figure 1        T cell migration 
 
Precursor T lymphocytes arise from the common lymphoid progenitor in the bone 
marrow. From the bone marrow, precursor T lymphocytes migrate to the thymus to 
mature into naïve T cells. Naïve T cells continuously circulate from the blood into 
the peripheral lymphoid tissues, such as the lymph nodes and spleen. After 
activation through encountering their cognate peptide-MHC complex, T cells 
migrate to extralymphoid organs, including the lungs, skin, liver, and gastrointestinal 
organs. 
 
 
  
	  4 	  
Figure 1        T cell migration 
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known as cytotoxic T cells, and after activation, CD8+ T cells kill the target cell. 
Both CD4+ and CD8+ T cells divide rapidly after activation, and give rise to memory 
T cells that persist long-term after an infection has resolved. 
 
The hallmarks of the adaptive immune system are specificity and memory. The 
specificity of T lymphocytes is determined by the TCR. In the thymus, naïve T cells 
are deleted when their TCR either does not bind MHC or binds MHC too strongly, a 
process called positive and negative selection, respectively(5). The selection 
process ensures that only T cells capable of recognizing “non-self” peptides 
complexed with MHC survive. The specific TCR alpha and beta chain expressed by 
a naïve T cell is generated from the somatic germline DNA that has undergone the 
process of both somatic hypermutation and V(D)J recombination. This mechanism 
allows a small number of genes to produce an extremely vast number of unique 
TCRs. Because these genetic rearrangements are an irreversible change to the 
DNA of an individual cell, all of the progeny from an individual T cell will have the 
same TCR specificity. Thus ensuring the “memory” of the adaptive immune system, 
because the clonal expansion of an activated T cell enables a faster response to the 
same antigen by having more of the antigen-specific T cells in circulation.  
T Cell Trafficking 
Naïve T cells circulate continuously from the blood into the peripheral lymphoid 
tissues, which they enter by squeezing between the specialized endothelial cells 
called high endothelial venules (HEV)	  (6). The interaction of naïve T cells with HEVs 
is critical for efficient T cell recirculation through lymph nodes. Naïve T cells are 
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activated when their antigen-specific TCR engages with the appropriate peptide-
MHC complex expressed by an antigen-presenting cell (APC). However, productive 
activation of a naïve T cell requires a second co-stimulatory signal to induce clonal 
expansion and differentiation into effector T cells (7). The constant movement of 
naïve T cells through lymph nodes ensures that as many T cells as possible are 
exposed to rare, foreign peptide-MHC complexes in an optimal environment for 
stimulation of naïve T cells. Once activated, effector T cells are collected in efferent 
lymphatics and enter the circulation through the thoracic duct. Activated T cells then 
traffic to extralymphoid organs, including the uninflamed lungs, skin, central nervous 
system and gastrointestinal organs, and can home to almost all inflamed organs 
and tissues. T cells are always on the move and the regulation of adhesion is critical 
for a T cell to get where it is going, and integrins are a family of adhesion receptors 
that mediate this process (1).   
Integrin-mediated Adhesion  
Integrins are the major cell adhesion receptors responsible for mediating cell-cell 
and cell-ECM interactions and essential to leukocyte growth, survival, activation, 
and migration.  Events such as T cell trafficking into lymphoid organs or sites of 
inflammation are generally mediated by β1 integrins (α4β1 integrin / VLA-4) binding 
to vascular cell adhesion molecule 1 (VCAM-1) and fibronectin (FN), or β2 integrins 
(αLβ2 integrin / LFA-1) binding to intercellular adhesion molecule 1 (ICAM-1) (8). 
The Leukocyte Adhesion Cascade 
Activated T cells enter extralymphoid tissues through a well defined cascade 
process beginning with a tethering or capture process to establish contact between 
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the T cell and the endothelial cell, followed by rolling, arrest, and eventually 
transmigration (figure 2)	  (9). T cell interactions with endothelium or APCs involve 
sequential, discrete steps beginning with brief, unstable interactions primarily 
mediated by L-selectin interacting with P-selectin glycoprotein ligand-1 (PSGL-1). 
Under conditions of shear flow, T cell interactions with the endothelium cause the T 
cells to roll across the endothelial surface, and it has been shown that α 4 integrins 
can mediate lymphocyte rolling (10,11). The tethering and rolling process of 
lymphocytes across the endothelial surface increases the chance of the lymphocyte 
encountering stimulation to induce integrin-mediated adhesion and arrest. 
Chemokines localized on the endothelial surface stimulate T cells leading to rapid, 
but transient, increases in integrin affinity and avidity. Following arrest, lymphocytes 
migrate through endothelial junctions and underlying basement membrane to enter 
tissue, a process known as extravasation, transmigration, or diapedesis. 
Integrins 
Integrins are cell surface receptors composed of α and β chain heterodimers and 
are type I transmembrane glycoproteins (12). In mammals, there are 18 different α 
and 8 different β subunits which combine to form at least 24 distinct αβ receptors 
(13). The heterodimers can be grouped into subgroups based on ligand- binding, 
subunit composition, or cell type expression (Figure 3). The ligand specificity is 
determined by the specific combination of α and β subunits, and therefore, the 
spectrum of integrin heterodimers expressed by a cell type largely determines how 
efficiently that cell can interact with a microenvironment	  (13). The α subunits vary in 
size between 120-180 kDa and are each noncovalently associated with a β subunit  
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Figure 2        The leukocyte adhesion cascade 
 
T cells enter tissues through a well defined cascade of events. The capture 
(tethering) is generally mediated by L-selectin forming rapid but weak interactions 
with specific carbohydrate epitopes on the endothelium. This leads to T cell “rolling” 
along the endothelium which enhances the likelihood of integrin-mediated arrest. 
Following arrest, T cells begin the process of integrin-mediated adhesion 
strengthening and cell spreading. Finally, T cells transmigrate through the 
endothelium and basement membrane into the tissue. 
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Figure 2        The leukocyte adhesion cascade 
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Figure 3      Integrin families 
 
Illustration of the 18 different α and 8 different β (24 distinct αβ receptors) grouped 
based on ligand-binding, subunit composition, and cell type expression.  
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Figure 3     Integrin families 
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of 90-100 kDa. Integrin subunits have large extracellular domains (approximately 
800 amino acids) that contribute to ligand binding, single transmembrane domains 
(approximately 20 amino acids), and short cytoplasmic tails (13 to 70 amino acids, 
except that of β4). All three domains are required for the activity of integrins (Figure 
4)	  (14). The α integrin subunit is composed of a seven-bladed β-propeller head, 
standing on a thigh, calf-1, and calf-2 domain. Half of the α integrin subunits contain 
an I-domain, which is almost always the ligand-binding site. The I-domain has a 
conserved metal ion-dependent adhesion site (MIDAS), and binds divalent cations 
required for ligand binding. The β integrin subunit is composed of a hybrid domain 
connected to the βI domain (analogous to the I-domain of the α integrin subunit), a 
PSI (plexin-semaphorin-integrin) domain, four cysteine-rich epidermal growth factor 
(EGF) domains, and a membrane proximal β tail domain (βTD). Integrins without an 
I-domain bind ligands in a crevice between the αβ subunit interface, where they 
interact with a metal-ion-occupied MIDAS within the β subunit and the propeller 
domain of the α subunit.  The short cytoplasmic tails of α and β integrin subunits 
share a high degree of similarity. Almost all β tails have two well-defined motifs that 
are part of a canonical recognition sequence for phosphotyrosine-binding (PTB) 
domains, consisting of a membrane proximal NPxY (where x is any amino acid) 
motif and membrane distal NxxY motif. These NxxY motifs are binding sites for 
multiple integrin-binding proteins. Integrins have no intrinsic kinase capacity and 
instead rely on the recruitment of many adapter proteins and kinases into large 
protein complexes drawing from a network of 156 identified components	  (15).  
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Figure 4        Integrin activation 
 
Illustration of an inactive (low affinity) integrin and an active (high affinity) integrin. 
The α integrin subunit is composed of a seven-bladed β-propeller head, standing on 
a thigh (genu), calf-1, and calf-2 domain. The β integrin subunit is composed of a 
hybrid domain connected to the βA domain (analogous to the I-domain of the α 
integrin subunit), a PSI (plexin-semaphorin-integrin) domain, four cysteine-rich 
epidermal growth factor (EGF) domains, and a membrane proximal β tail domain 
(βTD). Both subunits contain single transmembrane domains  and short cytoplasmic 
tails. Adapted from Moser, et al., 2009 (5). 
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Figure 4        Integrin activation 
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Inside-out Integrin Activation 
Integrin-mediated adhesion is regulated by a process known as inside-out signaling, 
and occurs either by a conformational change of the integrin determining the affinity 
of integrin for ligand or by avidity modulation due to receptor clustering (16). The 
extracellular binding activity of integrins is regulated from the inside of the cell 
(inside-out), while ligand-binding initiates signals that are transmitted into the cell 
(outside-in). Integrin affinity for ligand is regulated by conformational changes in the 
extracellular domain of the integrin heterodimer that exposes the ligand-binding site. 
Integrins exist in a bent, low-affinity conformation due to an interaction of the α and 
β cytoplasmic tails forming a salt bridge. Integrin activation occurs when the salt 
bridge is disrupted, resulting in the separation of the cytoplasmic tails and the 
unfolding of the extracellular domains exposing the ligand-binding site (17). Integrin 
activation leads to homodimerization of integrin transmembrane domains (α-to-α or 
β-to-β) resulting in clustering of integrins and formation of large protein complexes 
(18). Integrin clustering is important for induction of integrin recycling, outside-in 
signaling, and enhanced ligand binding (19). Talin is a large (~270 kDa) intracellular 
adaptor protein that is responsible for the separation of integrin cytoplasmic tails, 
linkage to the actin cytoskeleton, and recruitment of many key signaling proteins 
(20)	  (21). It has been shown that talin regulates cytoskeletal association, resistance 
to shear stress, and affinity of both α4β1 and LFA-1 (22)	  (23). 
Talin Structure 
Talin consists of a globular N-terminal ~50 kDa head domain and a ~200 kDa C-
terminal flexible rod domain (24). The talin head contains a FERM (4.1, ezrin, radixin, 
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moesin) domain composed of the F1, F2, and F3 subdomains.  FERM domains are 
found in a large number of cytoskeletal-associated proteins and are responsible for the 
localization of the protein to the plasma membrane by directly binding actin and 
cytoplasmic domains of integral membrane proteins.  The talin F3 FERM subdomain 
binds the cytoplasmic domain of β integrins, the hyaluronan receptor layilin, and the C-
terminal region of PIPK1γ90 (a splice variant of phoshpatidylinositol-4-phosphate 5 
kinase type Iγ) (25)	  (26)	  (27). The talin head binds β integrins through the talin F3 PTB 
(phosphotyrosine-binding) domain interacting with the membrane proximal NPxY motif 
of β integrins.  The talin head also contains an F-actin binding site, an adjacent 
membrane insertion sequence, and binds acidic phospholipids, PIP2, and RIAM (Rap1-
interacting adaptor molecule).  The talin head and rod domains are connected by a 
linker region, which contains cleavage sites for multiple proteases, including calpain-II.  
The talin rod contains 62 alpha-helices that are organized into a series of helical 
bundles, followed by a single C-terminal helix responsible for antiparallel 
homodimerization.  The talin rod contains an additional integrin-binding site (IBS), two 
actin-binding sites (ABS), and multiple vinculin-binding sites (VBS), as well as sites for 
several other talin-binding proteins.  The talin rod contains at least 3, but as many as 
11, VBS and vinculin itself has numerous binding partners including F-actin.   
Activation of vinculin by PIP2 promotes the binding of vinculin to the Arp2/3 complex, 
facilitating the nucleation of F-actin and driving the synthesis of F-actin at sites of 
activation (Figure 5)	  (28). 
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Figure 5        Integrin and talin activation 
 
Illustration depicting the events following integrin binding ligand. Subsequently, 
FAK/Src activation of PIPK1γ promotes the binding of PIPK1γ to talin and produces 
PIP2. PIP2 binds to and activates talin, leading to the exposure of talin domains 
resulting in talin binding b integrins, F-actin, and vinculin. Localized PIP2 activates 
vinculin to associate with and activate the Arp2/3 complex to nucleate actin 
polymerization. Adapted from Brakebusch and Fassler, 2003 (19). 
  
	  18 	  
Figure 5        Integrin and talin activation 
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Talin Activation 
Talin activation is tightly regulated by two major pathways: PIPK1γ90/PIP2 and 
Rap1/RIAM.  Like other FERM domain-containing proteins, talin exists in an auto-
inhibited conformation by an intramolecular interaction between the F3 subdomain and 
the talin rod domain(24). In this auto-inhibited conformation, the F3 PTB site is masked 
and unavailable to bind β integrins.  One model of talin activation is activated Src 
directly phosphorylating PIPK1γ90 leading to PIPK1γ90 binding talin F3 (26). The 
PIPK1γ90 binding site is exposed in the auto-inhibited conformation of talin and binding 
of PIPK1γ90 to talin results in the activation of PIPK1γ90, which drives translocation of 
the complex to the membrane and the localized synthesis of PIP2.  The binding of PIP2 
to talin F3 inhibits the talin head-rod interaction, thereby exposing the F3 IBS leading to 
talin binding β integrins and the activation of integrins (29). This interaction implies a 
positive feedback loop whereby activated Src promotes PIP2 synthesis and talin 
activation of integrin, resulting in adhesion and further activation of Src (30). Talin 
activation results in exposure of the F3 IBS and together with the IBS of the talin rod, 
talin homodimers have up to four IBSs, thereby providing a mechanism for crosslinking 
cytoplasmic domains of integrins to other integrins and F-actin, and the localized 
production of PIP2, facilitating the formation of focal adhesions. Similar to Src, the 
small GTPase Rap1, a Ras family member, is activated by a variety of upstream 
stimuli.  The association of Rap1 and RIAM promotes talin-dependent integrin  
activation. It has been shown that RIAM binding talin F3, even in the absence of Rap1, 
is sufficient to recruit talin to integrins and activate integrins (31).  
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Outside-in Integrin Signaling 
Integrin-mediated adhesion is also regulated by events following receptor 
occupancy that stabilize adhesion and coordinate cell spreading and migration, 
such as linkage of the integrin to the actin cytoskeleton and initiation of intracellular 
signaling (outside-in signaling) (Figure 6) (32) (33) (34). A common event in the 
outside-in signaling cascade is the activation of the Src and Syk family tyrosine 
kinases. Activation of these kinases results in the activation of many downstream 
pathways, including PI3K leading to AKT/PKB, Rac leading to JNK and NF-κB, and 
Ras leading to MAPK. Therefore, there are many possible functional responses 
resulting from outside-in integrin signaling. In leukocytes, outside-in integrin 
signaling usually occurs in the context of other stimulatory events involved in the 
inside-out pathway, such as activation of G protein-coupled receptors (GPCRs) or 
engagement of the TCR, so it has been difficult to distinguish the two. However, it 
has been shown in T cells that outside-in integrin signaling responses include 
activation of proliferation, IL-2 secretion, and stabilization of T cell/APC contacts. 
Signal transduction initiated by integrins is a dynamic process that is incompletely 
understood, and more so when considering each specific αβ integrin heterodimer or 
distinctly differentiated subset of activated lymphocytes may use a unique 
combination of interacting proteins to regulate each of these events (15).  
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Figure 6        Integrin-mediated adhesion (inside/out, outside/in) 
 
Integrin-mediated adhesion has three phases (blue arrows): (1) inside-out affinity 
regulation, (2) outside-in initiated by ligand-binding, and (3) secondary inside-out 
events leading to avidity modulation by receptor clustering and adhesion 
strengthening by recruitment of integrin associated proteins, such as talin and F-
actin. The outside-in signaling cascade culminates in the regulation of cell 
proliferation, survival, and migration by the activation of many downstream 
pathways, including PI3K leading to AKT/PKB, Rac leading to JNK and NF-κB, and 
Ras leading to MAPK. 
 
.   
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Figure 6        Integrin-mediated adhesion (inside/out, outside/in) 
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Mitogen-Activated Protein Kinase Pathway  
The mitogen-activated protein kinase (MAPK) pathway is activated by many cell 
surface receptor tyrosine kinases (RTKs) and is part of the outside-in signaling 
cascade initiated by integrin-mediated adhesion (35). The highly conserved 
Ras/Raf/MEK/ERK signaling module relays signals from the extracellular membrane 
to cellular effectors that regulate cell fate by influencing cellular proliferation, 
differentiation, apoptosis, and motility (Figure 7) (36). Receptor stimulation recruits 
guanine nucleotide exchange factors (GEFs) to exchange GDP for GTP and 
activate a membrane-bound RAS family member (N-RAS, H-RAS, K-RAS, RAP, 
RAL, RHEB), subsequently recruiting RAF family kinases to the plasma membrane 
for activation. Activated RAF then binds and activates MEK to bind and activate 
extracellular signal-regulated kinase (ERK), which then translocates to the nucleus 
and activates transcription factor complexes. Furthermore, the efficiency and 
outcome of MAPK pathway activation is also regulated by scaffolding proteins that 
stabilize and coordinate the assembly of the signaling complex	  (37). ERK has more 
than 150 substrates in the cytosol and nucleus, and it has become clear that the 
ERK pathway is not as linear as once thought.	  (38) 
RAF kinases 
The first RAF (rapidly accelerated fibrosarcoma) gene was described in 1983 as a 
retroviral oncogene, v-raf, transduced by the murine sarcoma virus 3611-MSV. This 
was the first oncogene to be discovered with serine/threonine kinase activity. In 
mammals, the RAF family of serine/threonine protein kinases consists of A-Raf (~68 
kDa), B-Raf (~75-100 kDa), and C-Raf/Raf-1 (~72-74 kDa), which share a common  
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Figure 7        Mitogen-activated protein kinase pathway 
 
The mitogen-activated protein kinase (MAPK) pathway is activated the outside-in 
signaling cascade initiated by integrin-mediated adhesion. The highly conserved 
Ras/Raf/MEK/ERK signaling module relays signals from the extracellular membrane 
to regulate cell fate by influencing cellular proliferation, survival, and motility.   
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Figure 7        Mitogen-activated protein kinase pathway 
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modular structure containing three conserved regions (CRs) (Figure 8). CR1 
contains a Ras-binding domain (RBD) necessary for the interaction with Ras and 
membrane phospholipids required for membrane recruitment, and a cysteine-rich 
domain (CRD) that is a secondary Ras-binding site and is necessary for the 
interaction of CR1 with the kinase domain for Raf auto-inhibition. The binding of Ras 
to the CRD is independent of the GDP/GTP status of Ras, and as Ras is 
predominantly attached to the inner leaflet of the plasma membrane, this binding 
recruits Raf to the membrane and is the initiating event of Raf activation. CR2 
contains inhibitory phosphorylation sites participating in the negative regulation of 
Ras binding and Raf activation. CR3 contains the kinase domain, including the 
activation segment and phosphorylation sites necessary for kinase activation. 
Functionally, the Raf structure can be split into a regulatory N-terminal region, 
containing CR1 and CR2, and a catalytic C-terminal region, containing CR3 and the 
kinase activity. In the inactive state, Raf is thought to exist in a closed conformation, 
stabilized by the scaffolding 14-3-3 proteins binding to CR2, in which the regulatory 
N-terminal region folds over and masks the catalytic C-terminal region. It has been 
shown that interaction of 14-3-3 with Raf is permissive for recruitment and activation 
by Ras, that 14-3-3 is displaced upon membrane recruitment, and 14-3-3 rebinding 
returns Raf to the inactive state and recycling to the cytosol	  (39).  
B-Raf 
B-Raf activation appears to be much simpler than activation of Raf-1 or A-Raf 
because the N-region of B-Raf is already negatively charged due to an aspartate 
(D449) at the position corresponding to a lysine in Raf-1/A-Raf, and the reported  
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Figure 8      B-Raf Structure 
 
(A) The common modular structure RAF family of serine/threonine protein kinases 
(A-Raf, B-Raf, and C-Raf/Raf-1). (B) The position of significant residues and regions 
in B-Raf. BRAF and CRAF share 73% base pair identity, and B-Raf and C-Raf 
share 60% amino acid (aa) identity, however, there are significant differences 
between the two that affect their regulation, activation, and activity (as discussed in 
the text. The amino acid sequence of B-Raf is shown below with conserved regions 
highlighted. 
 
 
         1 maalsggggg gaepgqalfn gdmepeagag agaaassaad paipeevwni kqmikltqeh 
       61 iealldkfgg ehnppsiyle ayeeytskld alqqreqqll eslgngtdfs vsssasmdtv 
      121 tsssssslsv lpsslsvfqn ptdvarsnpk spqkpivrvf lpnkqrtvvp arcgvtvrds 
      181 lkkalmmrgl ipeccavyri qdgekkpigw dtdiswltge elhvevlenv pltthnfvrk 
      241 tfftlafcdf crkllfqgfr cqtcgykfhq rcstevplmc vnydqldllf vskffehhpi 
      301 pqeeaslaet altsgsspsa pasdsigpqi ltspspsksi pipqpfrpad edhrnqfgqr 
      361 drsssapnvh intiepvnid dlirdqgfrg dggsttglsa tppaslpgsl tnvkalqksp 
      421 gpqrerksss ssedrnrmkt lgrrdssddw eipdgqitvg qrigsgsfgt vykgkwhgdv 
      481 avkmlnvtap tpqqlqafkn evgvlrktrh vnillfmgys tkpqlaivtq wcegsslyhh 
      541 lhiietkfem iklidiarqt aqgmdylhak siihrdlksn niflhedltv kigdfglatv 
      601 ksrwsgshqf eqlsgsilwm apevirmqdk npysfqsdvy afgivlyelm tgqlpysnin 
      661 nrdqiifmvg rgylspdlsk vrsncpkamk rlmaeclkkk rderplfpqi lasiellars 
      721 lpkihrsase pslnragfqt edfslyacas pktpiqaggy gafpvh 
 
CR1 – Ras-Binding Domain (RBD) aa 156-227 
CR2 – Cystine-rich aa 235-280 
CR3 – Catalytic Domain (activation segment) aa 457-715 
 
S445, T599, S602  
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Figure 8      B-Raf Structure 
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constitutive phosphorylation of S466, neutralizing the inhibitory role of the N-
terminal domain towards the catalytic domain. Thus making B-Raf activation solely 
dependent on Raf activity and phosphorylation of T598/S601, and explaining why a 
single activating mutation (V600E) is sufficient to render the kinase constitutively 
active. Indeed, B-Raf is an oncogene, while Raf-1 and A-Raf are not. It has been 
discovered that B-Raf is mutated at high frequency in human cancers, such as 
melanoma (30-60%), thyroid cancer (30-50%), colorectal cancer (5-20%), and 
ovarian cancer (~30%). Over 45 mutations have been described in B-RAF, but 
V600E accounts for ~90% of the B-RAF mutations observed in human cancer. 
Therefore, B-Raf is an important human oncogene and more research is needed 
into the complex regulation and biological functions of B-Raf. 
Non-canonical MAPK 
There is accumulating evidence that members of the MAPK pathway have 
secondary roles outside their described signaling module regulating transcription 
(40) (38). For example, Raf-1 can regulate mitosis and apoptosis independent from 
MEK, and MEK can regulate autophagy independent from RAF and ERK (41)	  (42) 
(43). In adherent cell lines, MAPK pathway members were shown to regulate 
motility and cytoskeletal dynamics by interacting with paxillin, myosin light chain 
kinase, and the Rho family of small GTPases (44) (45) (46) (47). However, our 
understanding of the role of MAPK in the regulation of lymphocyte adhesion or the 
direct regulation of integrin activity is still limited. Therefore, the goal of my research 
was to study possible secondary roles of the MAPK pathway members as 
regulators of integrin function in T cells.   
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Chapter 2 
 
B-Raf Regulation of Integrin-mediated Resistance to Shear Stress 
 
 
Introduction 
In Chapter 2, I show chemical inhibition of B-Raf, by low-dose Sorafenib, leads to 
reduced adhesion of Jurkat and normal human T cells to α4β1 integrin ligands 
VCAM-1 and fibronectin. I confirm the results seen with the inhibitor are mediated 
by B-Raf by knocking down B-Raf protein expression via sh-RNA transduction of 
Jurkat T cells. Finally, I confirm B-Raf is specifically regulating the α4β1 integrin, not 
other integrins, and this is not by regulating integrin affinity, integrin expression, or 
cell viability. 
Materials and Methods 
Reagents and Cells 
The human T cell line, Jurkat, was cultured in complete medium (RPMI 1640 
supplemented with 10% fetal bovine serum, 100 ug/ml penicillin and 100 ug/ml 
streptomycin). Human fibronectin was purified from plasma (Gulf Coast Blood 
Center, Houston, TX) as described (48). Normal human T cells were negatively 
selected from healthy donors (Gulf Coast Blood Center, Houston, TX) using the 
RosetteSep Human T-cell enrichment cocktail (Stemcell Technologies Inc., 
Vancouver, BC, Canada), then maintained in complete medium supplemented with 
human recombinant IL-2 (20 U/mL), anti-CD3 (1 ug/mL), and anti-CD28 (1 ug/mL). 
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Human VCAM-1 was purified from the supernatant of CHO cells engineered to 
express soluble VCAM-1-Fc (49). AlexaFluor- and HRP-conjugated secondary 
antibodies, non-specific rabbit and mouse IgGs, and mouse anti-GM1 were 
purchased (Invitrogen, Carlsbad, CA). The rabbit anti-p44/42 MAPK (Erk1/2), anti-
phospho-p44/42 MAPK, anti-phospho-B-Raf (pSER445), and anti-β-actin were 
purchased (Cell Signaling, Danvers, MA). Rabbit anti-B-Raf (clone EP152Y) 
(Epitomics, Burlingame, CA), mouse anti-CD59 and anti-α5 integrin (clone P1D6) 
(Santa Cruz Biotech, Santa Cruz, CA) were purchased. The mouse anti-α4 integrin 
(clone L25), anti-LFA-1 (clone MHM24), anti-CD3 (clone OKT3), anti-CD4 (clone 
OKT4), anti-β1 integrin (clone 33B6), anti-α4β1 integrin (clone 19H8), anti-αL 
integrin (clone 32E6), anti-CD43 (clone IB7), and anti-CD28 (clone 95F12) were 
purified from mouse ascites (50) (51) (52) (53). Doxycycline, puromycin, saponin, 
U0126 (Sigma-Aldrich, St. Louis, MO), and Sorafenib (LC Laboratories, Woburn, 
MA) were purchased.   
Generation of inducible B-Raf knockdown cells 
Knockdown cells were generated using shRNA-pTRIPZ clones (Open Biosystems, 
Huntsville, AL). Lentivirus was generated by Lipofectamine 2000 transfection of the 
packaging cell line, 293T-METR, with packaging plasmids containing pΔR8.91, 
CMV-pVSVG, and either scrambled non-silencing controls, or a BRAF targeting 
sequence. Viral supernatants were collected at 48 hours and concentrated by 
ultracentrifugation. Jurkat cells (1x106) were transduced then selected in medium 
containing puromycin (1 ug/ml). After one week, cells were divided into a no 
treatment group and a doxycycline (1 ug/ml) treated group. After 72 hours, 
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doxycycline-induced fluorescent red (TurboRFP) cells were purified with a FACS 
Aria IIu high-speed cell sorter (BD Bioscience) and cultured in complete medium 
with doxycycline.  
Parallel Plate Flow Detachment Assay 
The detachment assay was performed as described (54). In brief, human FN (5 
ug/ml), VCAM-1 (10 ug/ml), or mAbs (1 ug/mL) were immobilized to plastic slides, 
washed with PBS, blocked with 2% BSA in PBS, and assembled to a parallel plate 
flow chamber. Cells (4×106) in running buffer (10mM Tris, 103mM NaCl, 24mM 
NaHCO3, 5.5mM glucose, 5.4mM KCl, and 0.2% BSA, pH 7.4) were injected into 
the flow chamber and allowed to settle on the slide for 10 minutes. A computer 
controlled syringe pump (Harvard Apparatus) was used to apply an increasing linear 
gradient of fluid flow to the cells for 300 seconds and recorded by digital 
microscopy. Shear stress calculations were determined every 50 seconds and the 
shear stress in dynes/cm2 was defined as (6µQ)/(wh2), where µ is the viscosity of 
the media (0.007), Q is the flow rate in cm3/s, w is the width of the chamber (0.3175 
cm), and h is the height of the chamber (0.0254 cm).   
Soluble VCAM-1 Binding Assay 
The soluble VCAM-1 binding assay was modified from a previous procedure (55). In 
brief, cells (1×106) in 100uL serum-free media were incubated with human VCAM-1-
Fc (10 ug/mL) at 37°C for 10 minutes. The cells were then diluted and fixed by 
adding 2mL RPMI-1640 with 2% paraformaldehyde for 20 minutes at room 
temperature. The cells were washed twice with 2% BSA in PBS, and incubated with 
AlexaFluor 488 conjugated rabbit anti-mouse for 20 minutes at room temperature. 
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The cells were then washed and analyzed by flow cytometry using a FACSCalibur 
(BD Bioscience). 
Results 
RAF inhibition, but not ERK inhibition, leads to decreased adhesion of T cells to 
fibronectin 
The parallel plate flow assay was used to measure adhesion and investigate the 
role of ERK signaling in integrin-mediated adhesion to human FN under conditions 
of shear stress. Two inhibitors of the ERK pathway were used, U0126, a MEK 
inhibitor, and Sorafenib, a RAF inhibitor. Jurkat cell adhesion to FN was unchanged 
by one hour of 1uM U0126 treatment (Figure 9A). The U0126 and vehicle (DMSO) 
treated cells show very similar rates of detachment, with ~49% of the initial cells 
remaining at 45 dynes/cm2 (maximum shear) (Figure 9B). The phosphorylation of 
ERK was inhibited in these cells (Figure 9C). In contrast to MEK/ERK inhibition, 
adhesion to FN was significantly reduced by 50nM Sorafenib when compared to 
vehicle control (MeOH) (Figure 9D). The cells pretreated with vehicle show 47.5% 
of cells remaining at maximum shear, whereas the cells pretreated with Sorafenib 
show an increased rate of detachment with only 11.9% of cells remaining, a 75% 
inhibition (Figure 9E). The phosphorylation of B-Raf was inhibited by 50nM 
Sorafenib (Figure 9F). These results suggest RAF, and not MEK/ERK, contribute to 
T cell resistance to shear stress after adhesion to FN. 
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Figure 9      Sorafenib reduces adhesion to fibronectin 
 
   
Parallel plate flow detachment assay to slides coated with human FN (5 ug/mL) of 
Jurkat cells incubated for one hour with (A) U0126 (1uM) and DMSO vehicle control 
or (D) Sorafenib (50nM) and methanol vehicle control.  Percentage of cells 
remaining at 45 dynes/cm2 (maximum shear) from the parallel plate flow assay of 
cells incubated with (B) U0126 (1uM) and DMSO vehicle control or (E) Sorafenib 
(50nM) and methanol vehicle control.   Western blot using SDS-PAGE (10% gel) of 
whole cell lysates (1x107 cells) after 10 minutes adhesion to FN and pretreated for 
one hour with (C) U0126 (1uM) and DMSO vehicle control and probed for phospho 
and total ERK or (F) Sorafenib (50nM) and methanol vehicle control and probed for 
phospho and total B-Raf.  Error bars represent mean +/- SEM, *p<0.01 using the 
Student’s T-test.  
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Figure 9      Sorafenib reduces adhesion to fibronectin   
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RAF inhibition decreases α4β1 integrin-mediated adhesion to VCAM-1 
Both α5β1 and α4β1 integrin bind FN, so to address the specificity of the adhesion, 
we tested adhesion to VCAM-1, which is a ligand for α4β1 and not α5β1. Adhesion 
to VCAM-1 was unchanged by one hour of 1uM U0126 treatment (Figure 10A). The 
U0126 and vehicle (DMSO) treated cells show very similar rates of detachment to 
VCAM-1 with ~40% of cells remaining at maximum shear (Figure 10B). The 
phosphorylation of ERK was inhibited in these cells (Figure 10C). However, 
adhesion to VCAM-1 was reduced by 50nM Sorafenib (Figure 10D). The cells 
pretreated with either vehicle or 10nM Sorafenib show very similar rates of 
detachment to VCAM-1 with ~65% of the initial cells remaining at maximum shear, 
whereas the cells pretreated with 50nM Sorafenib show an increased rate of 
detachment with only 29.1% of the initial cells remaining, a 57% inhibition (Figure 
10E). The phosphorylation of B-Raf was inhibited at the 50nM concentration of 
Sorafenib (Figure 10F). Sorafenib is most specific for Raf-1 (6nM IC50) and B-Raf 
(22nM IC50) (56), and combined, these data suggest that B-Raf phosphorylation 
contributes to α4β1 integrin mediated adhesion to VCAM-1. 
B-Raf expression is increased after activation in Peripheral Blood T lymphocytes 
It has since been established that B-Raf is expressed by both normal T cells and 
several transformed T cell lines, yet the possibility of differential expression in T cell 
subsets remains. Therefore, B-Raf expression in normal T cells was examined in 
the CD4+ or CD8+ populations of unactivated PBMC or activated T cells negatively 
selected from the PBMC.  Both the CD4+ and CD8+ populations of the resting 
PBMC’s contain equal amounts of B-Raf after two and seven days of culture, but  
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Figure 10      Sorafenib reduces adhesion to VCAM-1 
 
 
Parallel plate flow detachment assay to slides coated with human VCAM-1 (10 
ug/mL) of Jurkat cells incubated for one hour with (A) U0126 (1uM) and DMSO 
vehicle control or (D) Sorafenib (10 or 50 nM) and methanol vehicle control.  
Percentage of cells remaining at maximum shear from the parallel plate flow assay 
of cells incubated with (B) U0126 (1uM) and DMSO vehicle control or (E) Sorafenib 
(10 or 50 nM) and Methanol vehicle control.   Western blot using SDS-PAGE (10% 
gel) of whole cell lysates (1x107 cells) after 10 minutes adhesion to VCAM-1 and 
pretreated for one hour with (C) U0126 (1uM) and DMSO vehicle control and 
probed for phospho and total ERK or (F) Sorafenib (10 or 50 nM) and methanol 
vehicle control and probed for phospho and total B-Raf.  Error bars represent mean 
+/- SEM, *p<0.01 using the Student’s T-test.  
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Figure 10      Sorafenib reduces adhesion to VCAM-1 
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the activated T cells show two levels, one equal to the PBMC and a second, higher 
level of B-Raf expression after two days, then both CD4+ and CD8+ populations 
transition to the higher expression level after seven days of culture (Figure 11). 
These results were consistent between three donors, therefore normal T cells 
express B-Raf and B-Raf expression is increased after activation. 
RAF inhibition leads to decreased adhesion of normal T cells to VCAM-1 and 
fibronectin 
Given the reported differences between Jurkat and non-transformed T cells, we 
investigated the response of normal human T cells to Sorafenib under conditions of 
shear stress after adhesion to α4β1 integrin ligands. Adhesion to both VCAM-1 
(Figure 12A) and FN (Figure 12B) was significantly reduced by 50nM Sorafenib, 
compared to MeOH vehicle control. Three healthy donors were tested and these 
results demonstrate Sorafenib reduces adhesion of normal human T cells to α4β1 
integrin ligands. 
BRAF knockdown decreases adhesion to VCAM-1 and fibronectin 
To confirm the role of B-Raf in α4β1 integrin-mediated adhesion, Jurkat cells were 
stably transduced with doxycycline inducible shRNA specific for BRAF or a 
scrambled shRNA vector control sequence with an RFP transduction efficiency 
marker (Figure 13) and then sorted based on RFP fluorescence (Figure 14 and 15). 
B-Raf protein expression was reduced in the B-Raf knockdown cells (KD) cultured 
with doxycycline by both western blotting (Figure 16A) and intracellular flow 
cytometry (Figure 16B). B-Raf knockdown cells (KD+D) compared to control cells 
(KD-NT, VC-NT, VC+D) show decreased adhesion to both VCAM-1 (Figure 17A)  
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Figure 11      B-Raf expression in normal human T cells 
 
Intracellular flow cytometry of total B-Raf (and isotype control) from the CD4+ or 
CD8+ populations of human resting peripheral blood mononuclear cells (PBMC) or 
activated T lymphocytes after 48 hours or 7 days of culture, data is shown from one 
healthy donor. Resting PBMC (orange and red) and CD3/CD28/IL-2 activated T 
cells (light blue and blue)  were stained with an isotype control (light blue and 
orange) or for total B-Raf (blue and red).  
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Figure 11      B-Raf expression in normal human T cells 
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Figure 12       Sorafenib reduces adhesion of activated normal human T cells 
to VCAM-1 and fibronectin 
 
 
Parallel plate flow detachment assay of activated normal human T cells pretreated 
for one hour with methanol vehicle control or Sorafenib (50nM), to slides coated 
with (A) human VCAM-1 (10 ug/mL) or (B) human FN (5 ug/mL). Data shown is an 
experiment performed in triplicate from one healthy donor, error bars represent 
mean +/- SEM. 
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Figure 12       Sorafenib reduces adhesion of activated normal human T cells 
to VCAM-1 and fibronectin 
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Figure 13       B-Raf knockdown vector 
 
Schematic representation of the pTRIPz vector. A nonsilencing shRNA sequence 
(RHS4743) was used as a transduction control, and the BRAF targeting shRNA 
sequence (V2THS_262034) CAGATGAAGATCATCGAAA was used to knockdown 
B-Raf protein expression. The B-Raf specific shRNA antisense sequence is: 
CAGATGAAGATCATCGAAA. The location of the binding sequence is shown 
below, and is confirmed to not exist in other protein sequences available through 
the Basic Local Alignment Search Tool (BLAST). 
 
NM_004333: 1107-1125 
 
     1021 acccgcctcg gactctattg ggccccaaat tctcaccagt ccgtctcctt caaaatccat 
     1081 tccaattcca cagcccttcc gaccagcaga tgaagatcat cgaaatcaat ttgggcaacg 
     1141 agaccgatcc tcatcagctc ccaatgtgca tataaacaca atagaacctg tcaatattga  
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Figure 13       B-Raf knockdown vector 
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Figure 14      Transduction of Jurkat T cells with B-Raf-specific shRNA 
 
Jurkat T cells were transduced with nonsilencing shRNA vector control (VC) and 
BRAF targeting shRNA vector (KD), then cultured with doxycycline (+D) to induce 
shRNA expression. Successful transduction was observed by the expression of 
RFP, both by flow cytometry for cell sorting and microscopy.  
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Figure 14      Transduction of Jurkat T cells with B-Raf-specific shRNA 
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Figure 15     Imaging of B-Raf knockdown cells 
 
 
The Jurkat cells transduced with B-Raf knockdown vector and cultured with (+dox) 
or without (NT) doxycycline are shown (same from Figure 14). 
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Figure 15      Imaging of B-Raf knockdown cells 
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Figure 16      Expression of B-Raf in transduced Jurkat T cells 
 
(A) Western blot using SDS-PAGE (10% gel) of whole cell lysates (1x107 cells) of 
Jurkat, vector control (VC), and B-Raf knockdown (KD) cells cultured with and 
without doxycycline (+/- D), and probed for total B-Raf or beta actin. (B) Intracellular 
flow cytometry of total B-Raf expression in cells cultured with doxycycline (red) or 
without doxycycline (blue), and isotype control antibody (grey and black, 
respectively).  
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Figure 16      Expression of B-Raf in transduced Jurkat T cells 
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Figure 17      B-Raf knockdown reduces adhesion to VCAM-1 and fibronectin 
 
 
Parallel plate flow detachment assay of VC and KD cells cultured with doxycycline 
(+D) or without doxycycline (NT) to slides coated with (A) human VCAM-1 (10 
ug/mL) or (B) human FN (5 ug/mL).  Percentage of cells remaining at maximum 
shear from the parallel plate flow assay of VC and KD cells to slides coated with (C) 
VCAM-1 or (D) FN.  Error bars represent mean +/- SEM, *p<0.01 using the 
Student’s T-test.  
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Figure 17      B-Raf knockdown reduces adhesion to VCAM-1 and fibronectin 
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and FN (Figure 17B). The control cells show very similar rates of detachment to 
VCAM-1 with ~55% of the initial cells remaining at maximum shear, whereas the 
KD+D cells show an increased rate of detachment with only 4.9% of the initial cells 
remaining (Figure 17C). Similarly, with FN, the control cells show equal rates of 
detachment with ~36% of the initial cells remaining at maximum shear, while the 
KD+D cells show an increased rate of detachment with only 7.4% of the initial cells 
remaining (Figure 17D). These results demonstrate that knockdown of B-Raf leads 
to decreased adhesion to α4β1 integrin ligands. 
B-Raf is unessential for T cell proliferation or α4 and β1 integrin expression 
A reduction in viability or α4β1 integrin expression of B-Raf knockdown cells could 
account for decreased adhesion. To confirm B-Raf knockdown did not produce a 
defect in cell viability, the proliferation of the transduced or control cells cultured with 
or without doxycycline was measured for ten days, and found to remain unchanged 
(Figure 18A). To confirm B-Raf knockdown does not lead to reduced surface 
expression of integrin subunits, α4 or β1 integrin subunits were measured by flow 
cytometry and was unchanged (Figure 18B). Thus, the decreased adhesion 
observed under conditions of B-Raf knockdown is not due to reduced viability or 
α4β1 integrin expression.  
α4β1 integrin affinity is not affected by B-Raf knockdown or Sorafenib 
Another mechanism of regulating the adhesion strength of integrins is the 
modulation of binding affinity. To test the role of B-Raf in the regulation of α4β1 
integrin affinity, the binding affinity for soluble VCAM-1 was measured and found to 
be unchanged by pretreatment with 50nM Sorafenib (Figure 19A) or by B-Raf   
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Figure 18      Cell proliferation and integrin expression is not affected by B-Raf 
knockdown 
 
Proliferation measured by trypan blue exclusion of (A) Jurkat, shRNA vector control 
(VC), and B-Raf knockdown (KD) cells cultured with and without doxycycline (+/- D) 
for ten days. Flow cytometry using a FACSCalibur (BD Bioscience) of (B) isotype 
control (ISO) (non-specific mouse IgG), and α4 (mAb L25) or β1 (mAb 33B6) 
integrin subunits stained with AlexaFluor 488 goat anti-mouse IgG secondary of 
vector control (VC) and B-Raf knockdown (KD) cells cultured with (+D) and without 
(NT) doxycycline.  Error bars represent mean +/- SEM.  
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Figure 18      Cell proliferation and integrin expression is not affected by B-Raf 
knockdown 
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Figure 19      Affinity for VCAM-1 is not affected by B-Raf knockdown or 
Sorafenib 
 
Soluble VCAM-1 (10 ug/mL) binding assay of (A) Jurkat cells incubated for one hour 
with Sorafenib (50nM) or methanol vehicle control, and (B) vector control (VC) and 
B-Raf knockdown (KD) cells cultured with doxycycline (+D) or without doxycycline 
(NT). Cells were incubated with secondary (2’) AlexaFluor 488 rabbit anti-mouse 
IgG and no soluble VCAM-1 to show background fluorescence, error bars represent 
mean +/- SEM. 
 
 
  
	  58 	  
Figure 19      Affinity for VCAM-1 is not affected by B-Raf knockdown or 
Sorafenib 
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knockdown (Figure 19B). Cells were incubated with Mn++ as a positive control for 
maximal integrin affinity, and the binding affinity for VCAM-1 of cells incubated with 
1mM Mn++ was increased over the cells that did not receive Mn++ but unchanged by 
B-Raf knockdown or Sorafenib, indicating the ability of the integrin to achieve a 
maximal affinity conformation is unaffected. These results indicate B-Raf is 
unessential to α4β1 integrin affinity for soluble VCAM-1 and the reduced adhesion 
is not due to affinity regulation of α4β1. 
Phosphorylation of paxillin (Tyr 118) after adhesion to VCAM-1 is not affected by B-
Raf knockdown or Sorafenib 
It is well known that paxillin can regulate integrin activity, and paxillin shows 
selectivity by only associating with specific integrin subunits, including α4	  (57). Also, 
it has been shown that Ras-induced serine phosphorylation of paxillin was mediated 
by induced expression of an activated B-Raf construct in a variety of cell types (58). 
Yet the function of this serine phosphorylation remains elusive and has been shown 
to not affect the ability of paxillin to associate with many previously identified binding 
partners. Phosphorylation of paxillin (Tyr 118) has been shown to be essential for 
actin cytoskeleton-dependent cell spreading and motility in lymphocytes by 
promoting the binding of the adapter protein Crk that subsequently recruits C3G, 
SOS, Dock2, Grb2, and others that can also activate Rac1, Ras, and Rap1 (59) (60) 
(61). Therefore, we investigated the phosphorylation of paxillin (Tyr 118) before and 
after adhesion to VCAM-1 using both Sorafenib treated and B-Raf knockdown cells. 
We found that adhesion to VCAM-1 induced phosphorylation of paxillin (Tyr 118), 
and this was unaffected by either Sorafenib or B-Raf knockdown (Figure 20). These  
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Figure 20      Phosphorylation of paxillin (Tyr 118) after adhesion to VCAM-1 is 
not affected by B-Raf knockdown or Sorafenib 
 
Western blot using SDS-PAGE (10% gel) of whole cell lysates (1x107 cells) of cells 
incubated for one hour with methanol vehicle control or Sorafenib (50nM (10 ug/mL) 
vector control (VC), and B-Raf knockdown (KD) cells cultured with doxycycline (+D) 
after 10 minutes of adhesion to VCAM-1 or BSA, and probed for total phospho-
paxillin (Tyr118), then stripped and reprobed for beta actin as a loading control. 
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Figure 20      Phosphorylation of paxillin (Tyr 118) after adhesion to VCAM-1 is 
not affected by B-Raf knockdown or Sorafenib 
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results demonstrate that α4β1 integrin can activate paxillin (Tyr 118) in the 
presence of B-Raf inhibition or knockdown. 
Sorafenib or B-Raf knockdown specifically reduces adhesion mediated by α4β1 
integrin 
Since α4β1 affinity was shown to be unaffected, this suggested we could bypass 
physiologic ligand coupling by using adhesion to immobilized mAbs to address the 
specificity of B-Raf inhibition on resistance to shear stress. Jurkat cell adhesion to 
an anti-α4β1 integrin mAb (19H8) was significantly reduced by 50nM Sorafenib 
when compared to vehicle control, while adhesion to an anti-CD28 mAb was 
unchanged by Sorafenib (Figure 21A). Adhesion was measured to mAbs to α4β1 
integrin (19H8), β1 integrin (33B6), α5 integrin, LFA-1 (32E6, MHM24), CD28, GM1, 
CD43, CD59, CD3 (OKT3), and CD4 (OKT4) (Figure 21B). Adhesion was only 
reduced by Sorafenib to α4β1 or β1integrin mAbs. Adhesion was also measured to 
the LFA-1 natural ligand ICAM-1, and found to be unaffected by Sorafenib (Figure 
21B). The shRNA vector control cells (VC+D) and B-Raf knockdown cells (KD+D) 
show equal detachment when bound to immobilized anti-LFA-1 (32E6), anti-CD3 
(OKT3), and ICAM-1 (Figure 21C). However, the adhesion of B-Raf knockdown 
cells to the anti-α4β1 integrin mAb (19H8) was significantly reduced when 
compared to shRNA vector control cells (Figure 21C). These results indicate B-Raf 
specifically regulates α4β1 integrin, and not other integrins or a variety of 
membrane components. 
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Figure 21      Sorafenib or B-Raf knockdown specifically reduces adhesion 
mediated by α4β1 integrin 
 
 
Parallel plate flow detachment assay (A) of Jurkat cells incubated for one hour with 
Sorafenib (50nM) and methanol vehicle control to slides coated with anti-α4β1 
integrin mAb (19H8) or anti-CD28 mAb (1 ug/mL). Percentage of cells incubated for 
one hour with Sorafenib (50nM) and methanol vehicle control remaining at 
maximum shear to slides coated with (B) anti-α4β1 integrin (19H8) (n=8), anti-β1 
integrin (33B6) (n=6), anti-α5 integrin (n=4), anti-LFA-1 (32E6) (n=4), anti-LFA-1 
(MHM24) (n=3), anti-CD3 (OKT3) (n=3), anti-CD4 (OKT4) (n=3), anti-CD28 (n=6), 
anti-CD43 (n=3), anti-CD59 (n=3), anti-GM1 (n=3), or human ICAM-1 (5 ug/mL) 
(n=6). Percentage of B-Raf knockdown (KD) or vector control (VC) cells cultured 
with doxycycline (+D) remaining at maximum shear to slides coated with (C) anti-
α4β1 integrin (19H8) (n=5), anti-LFA-1 (32E6) (n=4), anti-CD3 (OKT3) (n=4), or 
human ICAM-1 (5 ug/mL) (n=6). Error bars represent mean +/- SEM, *p<0.01 using 
the Student’s T-test. 
  
	  64 	  
Figure 21      Sorafenib or B-Raf knockdown specifically reduces adhesion 
mediated by α4β1 integrin 
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Discussion 
The results from this chapter have demonstrated B-Raf specifically regulates α4β1 
integrin-mediated T cell resistance to shear stress. The data presented in this 
chapter has revealed several important details of the mechanism (Figure 22). B-Raf 
was shown to specifically affect α4β1 integrin independent from regulating cell 
proliferation, integrin expression, integrin affinity, and paxillin activation. Importantly, 
B-Raf was shown to operate independently from downstream MEK and ERK. This 
is significant for many reasons, including both the implications for the role of B-Raf 
as an oncogene and the basic science contribution to this novel mechanism. Yet, 
the results confirming paxillin activation do not rule out that B-Raf is part of a 
downstream signaling event or complex mediated by α4-paxillin interaction. Indeed, 
it is intriguing to speculate that many of the known binding partners of paxillin can 
lead to activation of RAS/MAPK. The mechanism of how B-Raf regulates α4β1 
integrin function remains to be explored, and I will shed some light on this in the 
following chapters. 
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Figure 22      Model of B-Raf regulation of α4β1 integrin-mediated adhesion 
 
This figure summarizes the data presented in Chapter 2. The model for B-Raf 
regulation of α4β1 integrin has been updated to include independence from affinity 
regulation and downstream MEK/ERK activity. Because B-Raf was shown to 
specifically regulate α4β1 integrin-mediated adhesion, it is now reasonable to 
assume that the integrin depicted in this cartoon is only the α4β1 integrin, and not 
other integrins or surface proteins. Also, because B-Raf was shown to not regulate 
α4β1 integrin affinity, this suggests the mechanism is a post ligand-binding 
secondary adhesion strengthening event.   
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Figure 22      Model of B-Raf regulation of α4β1 integrin-mediated adhesion 
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Chapter 3 
 
B-Raf regulation of α4β1 integrin-dependent cell spreading 
 
 
Introduction 
In Chapter 3, I show B-Raf inhibition, by low dose Sorafenib, or B-Raf knockdown 
inhibits Jurkat T cell spreading on VCAM-1. I use super-resolution 
immunofluorescence to quantify the cell spreading, and show B-Raf specifically 
regulates α4β1 integrin-mediated cell spreading. Finally, using 3D reconstructions 
of super-resolution immunofluorescence, I show B-Raf inhibition reduces the 
amount of β1 integrin to colocalize with B-Raf. 
 
Materials and Methods 
Brightfield Microscopy 
Human VCAM-1 was immobilized to 6-well non-tissue culture treated plates 
(Falcon), washed with PBS and blocked with 2% BSA in PBS. Cells (1×106) in 
complete media were added and incubated at 37°C for 10 minutes, then fixed with 
2% paraformaldehyde in PBS for 20 minutes at room temperature.  Images were 
captured at 20x magnification using a Nikon Diaphot-TMD microscope, equipped 
with VI-470 CCD video camera (Optronics Engineering). Images were analyzed 
using Slidebook software (version 5.0) to distinguish spread cells from non-spread 
cells by creating a mask of spread cells and counting all cells that were larger or 
smaller than the threshold.  
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Super Resolution Immunofluorescence 
Human VCAM-1 (10 ug/mL), anti-α4β1 integrin mAb (19H8) (1 ug/mL), anti- α5 
integrin mAb (1 ug/mL), anti-LFA-1 mAb (32E6) (1 ug/mL), or anti-CD28 mAb (1 
ug/mL) was immobilized to glass coverslips, washed with PBS and blocked with 2% 
BSA in PBS. Cells (5×105) in complete media were added and incubated at 37°C 
for 10 minutes, then fixed with 2% paraformaldehyde in PBS for 20 minutes at room 
temperature. Cells were permeabilized by adding saponin to a concentration of 
0.1% for 30 minutes at room temperature. Cells were washed three times with PBS, 
2% BSA, 0.1% saponin, stained for total B-Raf (AlexaFluor 647), β1 integrin 
(AlexaFluor 488), and F-actin (AlexaFluor 594 conjugated phalloidin) then mounted 
to slides using Prolong Gold anti-fade reagent (Invitrogen). Images were acquired at 
room temperature using the OMX Blaze V4 structured illumination microscope 
(Applied Precision) with a 100x NA1.40 objective lens, two EM-CCD Photometrics 
Evolve 512 cameras, and DeltaVision OMX acquisition software.  The images were 
reconstructed, rotated in 3D by 90°, and the height of cells was measured using the 
softWoRx software (version 6.0 beta 19).  The image stacks were then transferred 
to either Slidebook software (version 5.0) to measure the area of contact of the cell 
with the glass coverslip or Imaris Bitplane software (version 7.6.1) to measure the 
colocalization of β1 integrin and B-Raf. The colocalization was quantified from the 
reconstructed 3D image using the spot detection function for absolute fluorescence 
of both β1 integrin and B-Raf channels. Spots were generated with a 200nm 
maximum XY diameter and a 500nm maximum Z diameter, identifying between 
2000 and 15,000 spots for each channel per reconstructed image. Then the spots-
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to-spots colocalization function was used to identify all spots within 300nm of spots 
from the other channel. 
 
Results 
Sorafenib or B-Raf knockdown inhibits cell spreading after adhesion to VCAM-1 
Brightfield microscopy was used to investigate the effects of RAF inhibition on cell 
morphology after adhesion to VCAM-1. Images were captured and quantified after 
10 minutes of adhesion to VCAM-1 (Figure 23A). An average of 84.4% of MeOH 
vehicle treated cells were spread, compared to 9% of cells treated with 50nM 
Sorafenib (Figure 23B). Similarly, an average of 77.3% of shRNA vector control 
cells (VC+D) were spread, compared to 7.9% of B-Raf knockdown cells (KD+D) 
(Figure 23C).  These results demonstrate B-Raf activity or expression is required for 
efficient α4β1 integrin-driven cell spreading. 
Sorafenib specifically inhibits α4β1 integrin-mediated cell spreading  
Super resolution microscopy was used to quantify the effects of RAF inhibition on 
cell morphology and spreading after 10 minutes adhesion to VCAM-1, anti-α4β1 
integrin mAb, anti-α5 integrin mAb, anti-LFA-1 mAb, or anti-CD28 mAb. Cell 
spreading after pretreatment with 50nM Sorafenib was measured using the height 
of cells and the area of cellular contact with the glass coverslip as indicators of 
spreading. The average height of cells after adhesion to VCAM-1 of cells pretreated 
with vehicle control (MeOH) was 5.5um, while the average height of cells pretreated 
with Sorafenib was 10.2um (Figure 24). The average area of cellular contact with  
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Figure 23      Sorafenib or B-Raf knockdown inhibits cell spreading on VCAM-1 
 
Brightfield microscopy after 10 minutes adhesion to VCAM-1 (10ug/mL) of (A) 
Jurkat cells pretreated for one hour with methanol vehicle control or Sorafenib 
(50nM) (left panels), and shRNA vector control (VC) or B-Raf knockdown (KD) cells 
cultured with doxycycline (+D) (right panels). Images were quantified and results 
shown as the mean percentage of cell spreading from two independent experiments 
performed in triplicate for (B) vehicle and Sorafenib treated cells and (C) control and 
B-Raf knockdown cells.  Error bars represent mean +/- SEM, *p<0.001 using the 
Students T-test. 
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Figure 23      Sorafenib or B-Raf knockdown inhibits cell spreading on VCAM-1 
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Figure 24      Super-resolution immunofluorescence of cells after adhesion to 
VCAM-1 
 
Super resolution immunofluorescence of β1 integrin (blue), B-Raf (red), and F-actin 
(green) of Jurkat cells incubated for one hour with methanol vehicle control or 
Sorafenib (50nM) then fixed after 10 minutes of adhesion to glass coverslips coated 
with VCAM-1 (10 ug/mL), (top) representative maximum intensity projection of 3D 
reconstructed images rotated by 90° to illustrate the height of cells, or (bottom) 
representative maximum intensity projection of the five Z-sections closest to the 
interface with the coverslip to illustrate the area of contact with VCAM-1. Scale bars 
represent 4um.  
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Figure 24      Super-resolution immunofluorescence of cells after adhesion to 
VCAM-1 
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VCAM-1 of control cells was 512um2, while the average with Sorafenib was 
110um2, a 78.4% reduction (Figure 24). Similarly, the average height of cells after 
adhesion to anti-α4β1 integrin mAb of cells pretreated with MeOH was 5.9um, while 
the average height of cells pretreated with Sorafenib was 9.8um (Figure 25). The 
average area of cellular contact with the anti-α4β1 integrin mAb of control cells was 
394um2, while the average with Sorafenib was 126um2, a 69.1% reduction (Figure 
25). However, the average height of cells after adhesion and the average area of 
cellular contact with the anti-α5 integrin (Figure 26), anti-LFA-1 (Figure 27), or anti-
CD28 (Figure 28) mAbs was not significantly affected by pretreatment with 
Sorafenib. Thus, the effects of Sorafenib were only observed after adhesion to an 
α4β1 integrin ligand (Figure 29). These results demonstrate B-Raf activity is 
specifically regulating α4β1 integrin-driven cell spreading. 
Sorafenib inhibits β1 integrin colocalization with B-Raf after adhesion to VCAM-1 
The effects of Sorafenib on the subcellular localization of β1 integrin and B-Raf 
were investigated after 10 minutes adhesion to VCAM-1. Image processing 
software was used to derive the digital data from the absolute fluorescence of 
super-resolution images, and the data was segmented and clusters of β1 integrin 
and B-Raf were visualized as spots inside the digital 3D environment  (Figure 30 
and 31). The spots-to-spots colocalization function was then used to identify all the 
spots generated from the β1 integrin fluorescence that were within a defined 
distance from the spots generated from the B-Raf fluorescence (Figure 32). The 
control cells had 31.6% of β1 integrin spots colocalize with B-Raf, and the cells 
pretreated with Sorafenib had only 13.3% of β1 integrin spots colocalize with B-Raf,  
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Figure 25      Super-resolution immunofluorescence of cells after adhesion to 
α4β1 integrin mAb 
 
Super resolution immunofluorescence of β1 integrin (blue), B-Raf (red), and F-actin 
(green) of Jurkat cells incubated for one hour with methanol vehicle control or 
Sorafenib (50nM) then fixed after 10 minutes of adhesion to glass coverslips coated 
with anti-α4β1 integrin mAb (1 ug/mL), (top) representative maximum intensity 
projection of 3D reconstructed images rotated by 90° to illustrate the height of cells, 
or (bottom) representative maximum intensity projection of the five Z-sections 
closest to the interface with the coverslip to illustrate the area of contact with VCAM-
1. Scale bars represent 4um.  
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Figure 25      Super-resolution immunofluorescence of cells after adhesion to 
α4β1 integrin mAb 
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Figure 26      Super-resolution immunofluorescence of cells after adhesion to 
α5 integrin mAb 
 
Super resolution immunofluorescence of β1 integrin (blue), B-Raf (red), and F-actin 
(green) of Jurkat cells incubated for one hour with methanol vehicle control or 
Sorafenib (50nM) then fixed after 10 minutes of adhesion to glass coverslips coated 
with anti-α5 integrin mAb (1 ug/mL), (top) representative maximum intensity 
projection of 3D reconstructed images rotated by 90° to illustrate the height of cells, 
or (bottom) representative maximum intensity projection of the five Z-sections 
closest to the interface with the coverslip to illustrate the area of contact with VCAM-
1. Scale bars represent 4um.  
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Figure 26      Super-resolution immunofluorescence of cells after adhesion to 
α5 integrin mAb 
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Figure 27     Super-resolution immunofluorescence of cells after adhesion to 
LFA-1 integrin mAb 
 
Super resolution immunofluorescence of β1 integrin (blue), B-Raf (red), and F-actin 
(green) of Jurkat cells incubated for one hour with methanol vehicle control or 
Sorafenib (50nM) then fixed after 10 minutes of adhesion to glass coverslips coated 
with anti-LFA-1 integrin mAb (1 ug/mL), (top) representative maximum intensity 
projection of 3D reconstructed images rotated by 90° to illustrate the height of cells, 
or (bottom) representative maximum intensity projection of the five Z-sections 
closest to the interface with the coverslip to illustrate the area of contact with VCAM-
1. Scale bars represent 4um.  
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Figure 27     Super-resolution immunofluorescence of cells after adhesion to 
LFA-1 integrin mAb 
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Figure 28     Super-resolution immunofluorescence of cells after adhesion to 
CD28 mAb 
 
Super resolution immunofluorescence of β1 integrin (blue), B-Raf (red), and F-actin 
(green) of Jurkat cells incubated for one hour with methanol vehicle control or 
Sorafenib (50nM) then fixed after 10 minutes of adhesion to glass coverslips coated 
with anti-CD28 mAb (1 ug/mL), (top) representative maximum intensity projection of 
3D reconstructed images rotated by 90° to illustrate the height of cells, or (bottom) 
representative maximum intensity projection of the five Z-sections closest to the 
interface with the coverslip to illustrate the area of contact with VCAM-1. Scale bars 
represent 4um.  
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Figure 28     Super-resolution immunofluorescence of cells after adhesion to 
CD28 mAb 
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Figure 29      Height and Area of Contact of cells after adhesion 
 
Super-resolution immunofluorescence images were analyzed for (A) the height of 
the cells when rotated by 90° in 3D, and (B) the area of contact at the interface of 
the glass coverslip. Data is shown from one experiment analyzing at least 10 
individual cells after 10 minutes adhesion to VCAM-1, anti-α4β1 integrin mAb 
(19H8), anti-α5 integrin mAb, anti-LFA-1 mAb (32E6), or anti-CD28 mAb. Error bars 
represent mean +/- SEM, *p<0.01 using the Student’s T-test.  
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Figure 29      Height and Area of Contact of cells after adhesion 
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Figure 30     Spot reconstructions of super-resolution immunofluorescence 
when rotated by 90° in 3D of cells after adhesion to VCAM-1 
 
The super-resolution immunofluorescence images of Jurkat cells incubated for one 
hour with methanol vehicle control or Sorafenib (50nM) then fixed after 10 minutes 
of adhesion to glass coverslips coated with VCAM-1 (10 ug/mL) were reconstructed 
in 3D using the Imaris Bitplane software, and the spot detection function was used 
to identify spots of high intensity fluorescence for β1 integrin (green) and B-Raf 
(red). The original super-resolution immunofluorescence images are shown followed 
by the spots identified from that image. Scale bars represent 4um. 
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Figure 30     Spot reconstructions of super-resolution immunofluorescence 
rotated by 90° in 3D of cells after adhesion to VCAM-1 
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Figure 31     Spot reconstructions of super-resolution immunofluorescence at 
the interface of the glass coverslip of cells after adhesion to 
VCAM-1 
 
The super-resolution immunofluorescence images of Jurkat cells incubated for one 
hour with methanol vehicle control or Sorafenib (50nM) then fixed after 10 minutes 
of adhesion to glass coverslips coated with VCAM-1 (10 ug/mL) were reconstructed 
in 3D using the Imaris Bitplane software, and the spot detection function was used 
to identify spots of high intensity fluorescence for β1 integrin (green) and B-Raf 
(red). The original super-resolution immunofluorescence images are shown followed 
by the spots identified from that image. Scale bars represent 4um. 
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Figure 31     Spot reconstructions of super-resolution immunofluorescence at 
the interface of the glass coverslip of cells after adhesion to 
VCAM-1 
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Figure 32      Colocalized β1 integrin and B-Raf spot reconstructions after 
adhesion to VCAM-1 
 
Colocalized spots for (left panel) total β1 integrin (green) and β1 integrin colocalized 
with B-Raf (yellow); and (right panel) total B-Raf (red) and B-Raf colocalized with β1 
integrin (yellow). Scale bars represent 4um. 
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Figure 32      Colocalized β1 integrin and B-Raf spot reconstructions after 
adhesion to VCAM-1 
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a 58% reduction (Figure 33). A trend was observed in the decreased amount of B-
Raf to colocalize with β1 integrin in Sorafenib treated cells, but failed to reach 
significance. These results demonstrate B-Raf activity is required for normal 
subcellular distribution of the β1 integrin. 
 
Discussion 
The results from this chapter have demonstrated B-Raf specifically regulates α4β1 
integrin-mediated cell spreading and B-Raf/β1 integrin colocalization. The data 
presented in this chapter has further revealed important details of the mechanism of 
B-Raf regulation of α4β1 integrin. The process of cell spreading is a complex event 
involving many proteins and signaling pathways. It has been shown in adherent cell 
types that ERK, Raf-1, and B-Raf can affect several of these cell spreading 
pathways, however this is the first demonstration to my knowledge of any MAPK 
members directly regulating integrin activity. The colocalization obviously could not 
be repeated with B-Raf knockdown cells; because there would be no B-Raf to 
visualize, however, future work includes analyzing B-Raf colocalization after 
adhesion to other integrins in T cells with inhibition of B-Raf activity. The imaging of 
F-actin lead to extremely complex data sets and both the B-Raf and β1integrin 
colocalization with F-actin was cumbersome and extremely computationally 
demanding. However, in the few images I did successfully accomplish this feat, I 
saw suggestive but not significant trends. Nevertheless, the imaging of F-actin 
revealed that B-Raf might affect actin cytoskeletal dynamics initiated by the α4β1 
integrin, and this will be investigated in Chapter 4. 
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Figure 33     Colocalization of β1 integrin and B-Raf after adhesion to VCAM-1 
 
 
The percentage of β1 integrin and B-Raf colocalization was determined by dividing 
the number of colocalized spots by the total number of spots. Data is shown from 
one experiment containing individual cells pretreated with methanol (n=10) or 
Sorafenib (n=14). Error bars represent mean +/- SEM, *p<0.01 using the Student’s 
T-test. 
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Figure 33     Colocalization of β1 integrin and B-Raf after adhesion to VCAM-1 
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Chapter 4 
 
B-Raf regulation of α4β1 integrin association with the cytoskeleton 
 
 
Introduction 
In Chapter 4, I show B-Raf inhibition, by low dose Sorafenib, reduces the amount of 
β1 integrin to associate with the actin cytoskeleton after stimulation through the β1 
integrin, and then confirm this phenomenon is mediated by B-Raf using B-Raf 
knockdown cells. I go on to show B-Raf specifically regulates α4β1 integrin 
association with the actin cytoskeleton, while having no effect on the association of 
α5 integrin, LFA-1, or CD28 with the cytoskeleton. 
 
Materials and Methods 
Cytoskeletal Stabilization Assay 
The quantification of integrin-cytoskeleton attachment was modified from a previous 
procedure (54)	  (55) (62). Cells (2×106) in 100uL complete media were incubated 
with mAb (1 ug/mL) at 4°C for 30 minutes, then either left untreated or AlexaFluor-
conjugated rabbit anti-mouse was added at 4°C for 30 minutes. The cells were 
incubated at either 4°C or 37°C for 10 minutes. The cells were then washed and 
resuspended in cytoskeletal stabilizing buffer (CSB) (50mM NaCl, 2mM MgCl, 
0.22mM EGTA, 13mM TRIS, 1mM PMSF, 10mM iodacetamide, and 2% FBS, pH 
8.0) with or without 0.1% NP-40. After 5 minutes at room temperature, 1mL CSB 
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was added, and cells were immediately pelleted and fixed with 2% 
paraformaldehyde in PBS for 20 minutes at room temperature. The cells were then 
washed three times in PBS and the amount of remaining bound mAb determined by 
flow cytometry using a FACSCalibur (BD Bioscience). 
 
Results  
Sorafenib prevents β1 integrin association with the cytoskeleton 
Integrin association with the actin cytoskeleton increases post-ligand binding and is 
necessary for focal adhesion formation and cellular resistance to shear stress. It 
has been shown that antibody crosslinking of α4 integrin on Jurkat cells leads to a 
significant increase in the amount of anti-α4 mAb able to resist solubilization by a 
non-ionic detergent, and is interpreted to result from an increase in α4 integrin 
association with the cytoskeleton (63). The association of β1 integrin with the 
cytoskeleton after activation by crosslinking of an anti-β1 mAb was measured. Cells 
pretreated for one hour with 50nM Sorafenib show significantly reduced β1 integrin 
association with the cytoskeleton after activation at 37°C (5.2%) compared to 
control (23.6%), a 78% reduction (Figure 34). These results show that RAF 
inhibition reduces β1 integrin association with the cytoskeleton, and indicate a role 
for B-Raf phosphorylation in this pathway. 
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Figure 34      Sorafenib reduces β1 integrin association with the cytoskeleton 
 
 
Cytoskeletal stabilization assay of Jurkat cells incubated for one hour with Sorafenib 
(50nM) and methanol vehicle control then incubated with AF-488 conjugated anti-β1 
integrin mAb and either crosslinked with an anti-mouse secondary mAb (X) or left 
untreated (NT) at 4°C or 37°C.  The percentage of NP-40 resistant mAb was 
determined by dividing the MFI of NP-40 treated cells by the MFI of cells that 
received no NP-40. Error bars represent mean +/- SEM, *p<0.001 using the 
Student’s T-test. 
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Figure 34      Sorafenib reduces β1 integrin association with the cytoskeleton 
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B-Raf is essential for β1 integrin association with the cytoskeleton 
The association of β1 integrin with the cytoskeleton was measured in B-Raf 
knockdown or shRNA vector control cells pretreated with 50nM Sorafenib or vehicle 
control. Consistent with results in Figure 34, shRNA vector control cells pretreated  
for one hour with Sorafenib show significantly reduced β1 integrin association with 
the cytoskeleton after activation at 37°C (4.2%) compared to vehicle control 
(20.5%), a 79.6% reduction (Figure 35). In comparison to vector control cells 
(20.5%), B-Raf knockdown cells show significantly reduced β1 integrin association 
with the cytoskeleton (6%) after activation at 37°C, a 71.8% reduction (Figure 35). 
These results indicate that B-Raf is essential for β1 integrin association with the 
cytoskeleton. 
Sorafenib specifically prevents α4β1 integrin association with the cytoskeleton 
The resistance to NP-40 solubilization was measured for mAbs to α4β1 integrin, 
LFA-1, CD28, and CD3. Compared to control cells at 4°C, crosslinking at 37°C 
significantly increased the amount of detergent resistant α4β1 (27.6% to 59%), LFA-
1 (31.3% to 60.8%), and CD3 (39.2% to 65.3%), but there was very little CD28 
association with the cytoskeleton (~4%) (Figure 36). Treatment with 50nM 
Sorafenib had little effect on the amount of detergent resistant LFA-1 (65.3%), 
CD28 (~2%), or CD3 (65.7%), while the amount of detergent resistant α4β1 mAb 
was significantly reduced (59% to 26.2%). These results show Sorafenib inhibits 
α4β1 integrin association with the cytoskeleton, and indicates phosphorylation of B-
Raf is specifically mediating the α4β1 integrin association with the cytoskeleton, 
while having no effect on LFA-1, CD28, or CD3 association with the cytoskeleton. 
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Figure 35      B-Raf knockdown reduces β1 integrin association with the 
cytoskeleton 
 
Cytoskeletal stabilization assay of vector control (VC) or B-Raf knockdown (KD) 
cells incubated for one hour with Sorafenib (50nM) and methanol vehicle control 
then incubated with AF-488 conjugated anti-β1 integrin mAb and anti-mouse 
secondary mAb at 4°C or 37°C.  The percentage of NP-40 resistant mAb was 
determined by dividing the MFI of NP-40 treated cells by the MFI of cells that 
received no NP-40. Error bars represent mean +/- SEM, *p<0.001 using the 
Student’s T-test. 
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Figure 35      B-Raf knockdown reduces β1 integrin association with the 
cytoskeleton 
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Figure 36      Sorafenib specifically reduces α4β1 integrin association with the 
cytoskeleton 
 
Cytoskeletal stabilization assay of Jurkat cells incubated for one hour with Sorafenib 
(50nM) and methanol vehicle control then incubated with AF-647 conjugated anti-
mouse secondary mAb and either anti-α4β1 (19H8), anti-LFA-1 (32E6), anti-CD3, 
or anti-CD28 mAb at 4°C or 37°C. The percentage of NP-40 resistant mAb was 
determined by dividing the MFI of NP-40 treated cells by the MFI of cells that 
received no NP-40. Error bars represent mean +/- SEM, *p<0.001 using the 
Student’s T-test. 
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Figure 36      Sorafenib specifically reduces α4β1 integrin association with the 
cytoskeleton 
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Discussion 
The results from this chapter have demonstrated B-Raf specifically regulates α4β1 
integrin association with the cytoskeleton. The data presented in this chapter has 
further revealed important details of the mechanism of B-Raf regulation of α4β1 
integrin (Figure 37). While the binding partners of this mechanism remain to be 
discovered, these data are a novel discovery that should pave the way for the 
discovery of the interacting proteins. On a side note, the data showing CD28 did not 
associate with the cytoskeleton was unexpected, and I have not been able to find 
data in the literature concerning this. However, the lack of cytoskeletal linkage 
observed from crosslinking our CD28 antibody might be a consequence of our 
specific experimental conditions, or specific to the monoclonal antibody. All surface 
glycoproteins have distinct physicochemical associations with the membrane or 
underlying cytoskeletal components. Therefore, it is possible that cytoskeletal 
remodeling induced by soluble crosslinking of CD28 may differ from that induced by 
plate-bound antibodies, or alternatively stabilization may not be optimal with the 
concentration or kinetics of membrane denaturants and cytoskeletal stabilizers we 
used. The significance and implications of my research will be discussed in Chapter 
5. 
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Figure 37      Model of B-Raf regulation of α4β1 integrin 
 
 
The model for B-Raf regulation of α4β1 integrin should now be considered in the 
context of actin cytoskeletal dynamics and the direct association of α4β1 integrin 
with the actin cytoskeleton. This mechanism is a post ligand-binding secondary 
inside-out adhesion strengthening event specific to the α4β1 integrin. B-Raf has 
been shown to regulate the association of the α4β1 integrin with the actin 
cytoskeleton, cell spreading, and resistance to shear stress when bound to an α4β1 
integrin ligand. 
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Figure 37      Model of B-Raf regulation of α4β1 integrin 
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Chapter 5 
Discussion and Future Directions 
Discussion 
General 
This work has demonstrated a novel role for B-Raf in the direct regulation of the 
α4β1 integrin in lymphocytes. Both the chemical inhibition and knockdown of B-Raf 
lead to decreased resistance to shear stress of T cells after adhesion to α4β1 
ligands and decreased α4β1 association with the cytoskeleton after mAb 
crosslinking. These effects were both specific for α4β1 integrin and independent 
from affinity regulation or downstream MEK/ERK activity. We have also shown 
Sorafenib inhibits α4β1 integrin-driven cell spreading and β1 integrin colocalization 
with B-Raf.  The increased height and reduced area of cellular contact with VCAM-1 
of cells treated with Sorafenib suggest these cells are experiencing greater shear 
stress distributed over a smaller area of anchorage, likely contributing to decreased 
adhesion in our laminar flow system. Cell adhesion has been shown to be 
dependent on the dynamics of the actin cytoskeleton and cell spreading, promoting 
adhesion strengthening and migration, in part by providing a more streamlined 
shape for the cell to reduce the shear stress imposed by laminar flow (34)	  (64) (65).  
How does B-Raf regulate α4β1 integrin function 
At present, it is not clear on the molecular level how B-Raf regulates α4β1 integrin 
function.  Chemokine binding to GPCRs induces the activation of phospholipase C 
and calcium signaling leading to the rapid upregulation of α4β1 and LFA-1 integrin 
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affinity	  (66)	  (67). Downstream of calcium signaling, Rap1 plays an important role in 
β2 integrin affinity regulation and adhesion, but this has not been established for 
α4β1 integrin (32)	  (68). It has been shown that Rap1 mediates phorbol-ester (PMA) 
stimulated adhesion to FN, but Rap1 does not mediate SDF-1α stimulated affinity 
upregulation of α4β1 integrin for VCAM-1 or adhesion to VCAM-1 after SDF-1α or 
PMA stimulation	  (69)	  (70). However, Rap1 specifically activates B-Raf, not Raf-1, 
and precedence for RAF family members in adhesion regulation was provided by 
studies demonstrating that H-Ras activation of Raf-1 suppressed integrin activation 
in CHO cells, but there were conflicting results concerning whether the suppression 
was independent of ERK (71)	  (72)	  (73)	  (74)	  (75). Therefore, a secondary role for B-
Raf in the direct regulation of integrin-mediated adhesion was feasible.   
B-Raf is specifically regulating α4β1 integrin 
Identification of the specific B-Raf containing complex and binding partners of this 
mechanism will be important to the understanding of lymphocyte adhesion. Our 
results indicate that B-Raf is specifically regulating the α4β1 integrin, and not LFA-1 
or a variety of other membrane proteins.  Integrin cytoplasmic tails binding to 
integrin-associated proteins mediate the events following receptor occupancy, such 
as adhesion strengthening and outside-in signaling. It has been shown that talin 
regulates cytoskeletal association, resistance to shear stress, and affinity of both 
α4β1 and LFA-1	  (22)	  (23). Yet, it is established that different integrin heterodimers 
expressed by the same cells can utilize distinct signaling components and 
downstream effectors. For example, paxillin binding to α4 integrin cytoplasmic 
domains is known to regulate cytoskeletal association and resistance to shear 
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stress but not affinity of α4β1, while paxillin does not bind to αL of LFA-1	  (33) (63) 
(57).   
Novel interactions of B-Raf in T cells 
In addition to possible Rap1 interaction, novel binding partners of B-Raf in T cells 
have been found	  (76). Of interest, B-Raf was shown to interact with both Dock2 
(dedicator of cytokinesis protein 2), a guanine nucleotide exchange factor known to 
specifically activate Rac, and IQGAP1 (Ras GTPase-activating-like protein 1), a 
scaffolding protein known to interact with actin, Rac1, calmodulin, and Src (76) (77) 
(78). Alternatively, B-Raf regulates cytoskeletal dynamics in melanoma cells by 
mediating crosstalk with the Rho/ROCK pathway through Rnd3, and in fibroblasts 
through the ROCKII/LIMK/cofilin pathway (47) (79). While other studies using 
adherent cell lines have identified Raf-1 association with vimentin, myosin 
phosphatase, and the Rho-effector Rok-α, raising the possibility of similar 
interactions for B-Raf (80)	  (81)	  (82). Altogether, and given the inherent differences 
between how adherent cell types and lymphocytes regulate adhesion, more studies 
are required to explore the molecular details of how B-Raf and α4β1 integrin interact 
in T cells. 
B-Raf in T cells 
The activities of all Raf isoforms are subject to complex regulation but have been 
shown to be dependent on Ras activity for the initiation of Raf activation. The 
activation of both A-Raf and Raf-1 requires phosphorylation on the B-Raf 
corresponding residue Ser455, but this residue has been shown to be constitutively 
phosphorylated on B-Raf in many cell types (83)	  (84). Therefore, B-Raf activation is 
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solely dependent on Ras activity and phosphorylation of T598/S601 (40).  
Constitutive activation of MAPK signaling by mutant forms of B-Raf (i.e. V600E) is 
observed broadly in solid cancers of multiple primary sites (85) (86). Leukemias of 
lymphoid origin express B-Raf and other than the recent discovery of hairy-cell 
leukemia, mutations of the BRAF gene are very rare, suggesting a fundamental and 
conserved role in T cell leukemia and possibly normal T cell function (87) (88) (89) 
(90) (91) (92) (93). While there are few studies that focus on the importance of B-
Raf to T cell physiology, it has been shown that MAPK signaling during T cell 
development progression beyond the CD4-CD8 double positive stage requires B-
Raf, and rescue experiments with B-Raf can restore proliferation through MAPK 
signaling in anergic T cells	  (73) (93).   
B-Raf inhibitors 
Specific inhibitors of mutant B-Raf were approved for treatment of melanoma in 
2011, while general RAF inhibitors have been clinically used since 2007 (94) (95) 
(96). Chemical inhibition of MEK or RAF results in the inhibition of ERK and is 
sufficient to stop proliferation of many cancer cells (97). Sorafenib is a multi-kinase 
inhibitor once higher concentrations have been reached, but is most specific for C-
Raf (6nM IC50) and B-Raf (22nM IC50), and is still used in the clinic for the 
treatment of advanced renal cell carcinoma or hepatocellular carcinoma (56). The 
findings presented in this work should cause a reevaluation of clinical use of 
Sorafenib having potential off-target effects on T cells (98)	  (99)	  (100). The effects of 
Sorafenib on α4β1 integrin could impact T cell migration and homing to sites of 
inflammation or potentially effector functions	  (101)	  (102) (103). This is significant 
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because the selectivity of this interaction may provide a therapeutic target for α4 
integrin related diseases, such as asthma, multiple sclerosis, rheumatoid arthritis, 
inflammatory bowel disease, and certain leukemias and lymphomas (4). Given that 
we have focused on Sorafenib inhibition of B-Raf Ser445 and the rarity of B-Raf 
mutations in T cells, this work also suggests that specific V600E B-Raf inhibitors 
may have less off-target effects on T cells (104).   
Scope of my studies 
We propose a novel secondary role for B-Raf in the upregulation of cytoskeletal 
association of α4β1 and cell spreading mediated by the α4β1 integrin to regulate 
resistance to shear stress. Interestingly, this effect is independent from downstream 
MEK/ERK signaling, and within the scope of our studies, this association is unique 
to α4β1 integrin and not to other integrins or unrelated surface proteins. Both α4β1 
integrin and B-Raf play important roles in human diseases, and understanding the 
mechanisms of their functions will provide important insights into the adaptive 
immune response and design of therapeutic strategies. 
Future Directions 
Targeting α4β1 integrin through B-Raf 
This research directly implicates novel therapeutic targets in higher-level functions 
of immune cells for the development of applicable clinical interventions. However, in 
the specific case of drugging B-Raf to modulate α4β1-mediated adhesion, potential 
clinical utility is not defined by the experiments I have conducted. Yet the selective 
expression of α4β1 on T cell subsets could provide a direction for further study. If, 
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as my data indicates, that through drugging B-Raf this adhesion event could be 
blocked in patients, it may offer an opportunity for new trials for existing drugs. The 
rational inhibition of specific adhesion events could selectively effect immune cells 
in acute cases of immunological disease and avoid sledgehammer-type approaches 
to immune suppression. Given that advances in immune monitoring technologies 
could predict the accumulation of pathogenic T cells prior to clinical symptoms, 
more sophisticated early interventions, may be possible. At this time there are no 
registered clinical trials underway to test Sorafenib (BAY 43-9006) in any 
autoimmune disease. 
Using the α4β1 integrin-B-Raf interaction in inflammatory brain disease 
In autoimmune diseases, pioneer T cells are the first to enter a future site of 
inflammation. Best understood in the central nervous system (CNS), pioneer T cells 
are defined by their ability to home to these tissues. Upon entry, these cells induce 
inflammatory conditions that are required for the entry of more T cells, which 
mediate the pathogenesis of experimental autoimmune encephalomyelitis (EAE) 
(105). The α4β1 integrin is required for this secondary pathogenesis, but not the 
entry of pioneer T cells. Upon early detection, B-Raf inhibition could be used as a 
tool to prevent this entry of T cells into the CNS which manifests symptomatic 
inflammatory brain disease.   
Using the α4β1 integrin-B-Raf interaction in other diseases 
However, the function of suppressive cells in the immune system could be 
compromised by such approaches. For instance, work on human T cells has shown 
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that unique Treg subsets can be functionally defined by expression of either α4β1 or 
α4β7 integrins. These Treg subsets have the ability to convert naive CD4 cells to 
either TGF-beta producing or IL-10 producing suppressor cells respectively 
(106,107). Yet, encouragingly, these integrins serve as markers and not the 
effectors of their suppressive mechanisms, as it was clearly shown that cell contact, 
though necessary in in vitro conditions for suppression are not required in vivo 
(108). Yet, it has also been shown in murine cancer models that Sorafenib can 
deplete Tregs and MDSCs (102). As the dose of this agent is crucial to enforce the 
selective B-Raf inhibitory function, such evidence of these non-homing related, 
immune cells depletion is well documented (109). Nevertheless, this approach to 
modulate α4β1 by B-Raf inhibition could be performed by more selective drugs 
developed for melanoma and thyroid cancer. In the repurposing of these agents, the 
success of the humanized α4 integrin monoclonal antibody Natalizumab (Tysabri) in 
the treatment of multiple sclerosis and Chron’s disease may be replicated without 
the same profound immunosuppressive side effects, such as causing progressive 
multifocal luekoencephalopathy	  (110). 
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